Announced
Synopsis
Melinta Therapeutics, an American biopharmaceutical firm, terminated the $57m acquisition of Tetraphase Pharmaceuticals, a biopharmaceutical company. “This transaction increases our world-class infectious disease portfolio and we are eager to build upon our synergies and leverage our collective expertise and scale to offer patients and providers battling serious bacterial infections with an additional potentially life-saving treatment option,” Jennifer Sanfilippo, Melinta Interim CEO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.